Should I Buy ONC? ONC 2026 Analysis

Should You Buy BeOne Medicines AG (ONC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

349.470

1 Day change

-0.15%

52 Week Range

385.220

Analysis Updated At

2026/01/26

BeOne Medicines AG (ONC) is not a strong buy at the moment for a beginner, long-term investor. While the company has strong growth potential in its pipeline and positive analyst ratings, the recent financial performance, hedge fund selling trends, and lack of strong trading signals suggest that it may be better to wait for a more favorable entry point.

Technical Analysis

The stock's technical indicators show mixed signals. The MACD is positive and contracting, indicating a bullish trend. The RSI is neutral at 56.322, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its pivot point (339.407), with limited short-term upside potential based on resistance levels (R1: 350.103, R2: 356.711).

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The high Open Interest Put-Call Ratio suggests bearish sentiment, while the low Option Volume Put-Call Ratio indicates more call activity today. The implied volatility percentile is 66.21, suggesting moderately high options activity.

Technical Summary

Sell

Buy

Positive Catalysts

Analysts have consistently raised price targets, with the latest targets ranging from $390 to $420, reflecting confidence in the company's growth potential.
Strong revenue growth in Q3 2025, up 41% YoY.
Leadership in chronic lymphocytic leukemia (CLL) and a promising pipeline with potential approvals in 2026.

Neutral/Negative Catalysts

Hedge funds are selling heavily, with a 7307.41% increase in selling activity last quarter.
Net income dropped significantly (-202.88% YoY), and EPS declined (-188.89% YoY), indicating profitability concerns.
Lack of recent news or event-driven catalysts to drive immediate price appreciation.

Financial Performance

In Q3 2025, revenue increased by 41% YoY to $1.41 billion, showcasing strong top-line growth. However, net income dropped significantly (-202.88% YoY) to $124.84 million, and EPS declined to 0.08 (-188.89% YoY), reflecting challenges in profitability. Gross margin improved slightly to 86.09%, up 3.75% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are bullish on BeOne Medicines, with multiple firms raising price targets recently (ranging from $390 to $420) and maintaining Buy or Overweight ratings. Analysts highlight the company's strong CLL franchise, promising pipeline, and potential for positive free cash flow by 2025. However, near-term profitability concerns remain.

11 Analyst Rating

Wall Street analysts forecast ONC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONC is 403.76 USD with a low forecast of 385 USD and a high forecast of 424 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

0 Hold

0 Sell

Strong Buy

Current: 350.000

Low

385

Averages

403.76

High

424

Current: 350.000

Low

385

Averages

403.76

High

424

Morgan Stanley

Overweight

maintain

$390 -> $405

AI Analysis

2026-01-08

Reason

Morgan Stanley

Price Target

$390 -> $405

AI Analysis

2026-01-08

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on BeOne Medicines to $405 from $390 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

Truist

Buy

initiated

$400

2025-11-24

Reason

Truist

Price Target

$400

2025-11-24

initiated

Buy

Reason

Truist initiated coverage of BeOne Medicines with a Buy rating and $400 price target. The firm expect Brukinsa's revenue stream to sustainably support the company's operations and drive BeOne Medicines toward the guided positive free cash flow by 2025, the analyst tells investors in a research note. The company's leadership position in CLL - chronic lymphocytic leukemia - is well-solidified by Brukinsa's differentiation and the franchise's comprehensive growth strategy, including proprietary next-wave assets such as sonrotoclax and BTK CDAC, Truist added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ONC

Unlock Now

ONC Should I Buy

ONC Should I Buy

Should You Buy BeOne Medicines AG (ONC) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch